Slingshot members are tracking this event:
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
Slingshot Insights Explained
Aug 22, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Fast Track Status, Azd3293, Bace Inhibitor, Oral Beta Secretase Cleaving Enzyme